EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Cytoflavin's neuroprotective effect in acute ischemic stroke: a systematic review and meta-analysis

Retnaningsih Retnaningsih, Dodik Tugasworo, Wati Arinta Puspita, Chandra Elvika, Arrizki Azka Pratama

Frontiers in Stroke · 2026-10-30 · 5

DOI: 10.3389/fstro.2026.1775376 ↗
AbstractBibliografische Angaben

Abstract

Acute ischemic stroke (AIS) remains a leading cause of long-term disability globally. While reperfusion therapies are effective, there is a growing need for adjunct neuroprotective strategies to minimize secondary brain injury. Cytoflavin, a metabolic and antioxidant compound, has shown potential neuroprotective effects. However, its clinical efficacy remains underexplored. This systematic review and meta-analysis aim to evaluate the efficacy of Cytoflavin in AIS, focusing on neurological recovery (NIHSS), functional independence (Barthel Index), cognitive performance (MMSE), and infarct volume. A systematic search was conducted across multiple databases for studies evaluating Cytoflavin in AIS. Nine studies were included, with a combined enrollment of 3,254 participants across treatment arms (sample sizes reported per arm); the number of unique participants contributing to each pooled outcome was smaller after correcting for shared control groups and repeated-measures overlap across evaluation time points (e.g., 1,379 for NIHSS). Data were analyzed using random-effects models; where a shared control group was compared against two Cytoflavin dose arms within the same study, the control group was split proportionally between the two comparisons to avoid double-counting participants (unit-of-analysis correction). Risk of bias was assessed using Cochrane Risk of Bias tool and Newcastle-Ottawa Scale. Cytoflavin significantly improved NIHSS scores (MD = −2.63, 95% CI: −3.15 to −2.10; moderate certainty) and Barthel Index (MD = 19.29, 95% CI: 9.52 to 29.07; moderate certainty), and showed improvements of low certainty in MMSE scores (MD = +6.93, 95% CI: 1.39 to 12.47) and mRS scores (MD = −0.41, 95% CI: −0.74 to −0.09), the latter derived from continuous summary statistics for an inherently ordinal scale (see Limitations). For infarct volume, effects diverged by evaluation time point: a marginal increase was observed at Day-10 (MD = +0.17 cm 3 , based on a single study), while a non-significant reduction was observed at Day-21 (MD = −4.73 cm 3 , 95% CI: −11.41 to 1.95; very low certainty). High heterogeneity (I 2 ranging from 0% to 100%) was observed across outcomes and persisted after the unit-of-analysis correction, indicating genuine clinical and methodological diversity across studies. In conclusion, cytoflavin shows promising neuroprotective effects in AIS. However, due to heterogeneity and methodological limitations, further large-scale, high-quality studies are needed to confirm its efficacy and optimize treatment protocols. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251112430 , identifier: CRD420251112430.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →